Amgen has selected West’s Daikyo Crystal Zenith (CZ) vials, in conjunction with West FluroTec stoppers, to contain its FDA-approved therapy IMLYGIC (talimogene laherparepvec), indicated for nodal lesions in patients with melanoma. CZ vials are manufactured from a cyclic olefin polymer and offer a break-resistant, high-performance alternative to glass for complex drugs.

The CZ container closure system also includes a West FluroTec stopper, which provides a barrier against extractables without compromising seal integrity, according to the company, maintaining the full strength of biologic therapies. Additionally, the CZ vial can withstand cold storage environments.
 
“West recognizes the growing demand for high quality and technologically advanced containment systems for today’s sophisticated biologic drugs, particularly when there may be challenges of interaction or adsorption related to traditional glass vials,” said John Paproski, senior vice president and chief technology officer, West. “Daikyo Crystal Zenith technology represents an important way to address the needs of our customers in this growing biotechnology market.”
 
“We appreciate the relationship we have with West and how they have worked with us to provide an appropriate container closure solution to address the ultra-cold storage conditions for IMLYGIC,” said Bill Rich, vice president, Device Technologies at Amgen.